Previous 10 | Next 10 |
Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS) - Negative Outcome on Primary Endpoint Measured by the Change...
Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference PR Newswire SAN DIEGO , Feb. 23, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 41 st Annual Health Care Conference at 1:30 p.m. Ea...
Neurocrine had already informed investors about weak fourth quarter Ingrezza sales, but AbbVie sales of Orilissa and Oriahnn were weak again, and Ongentys missed expectations as well. Management is upping its marketing spend, likely focusing on getting docs more comfortable with presc...
Neurocrine Biosciences ([[NBIX]] +1.4%) is trading higher today despite the Q4 2020 revenue miss as announced yesterday.However, keeping the outperform rating, the analysts at Baird expect the sales to rebound in the coming year as COVID-driven headwinds subside. The price target is...
Neurocrine Biosciences ([[NBIX]] +1.6%) reports Q4 total revenue of $247.9M, +1.6% Y/Y, misses consensus by $20M.GAAP R&D $66.7M vs. last year's $55.3M.Non-GAAP R&D of $59.4 vs. last year's $47.9M.At December 31, 2020, the Company had cash, cash equivalents and debt securities av...
Image source: The Motley Fool. Neurocrine Biosciences Inc (NASDAQ: NBIX) Q4 2020 Earnings Call Feb 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Neurocrine Biosciences Inc (NBIX) Q4 2020 Earnings Call Transcrip...
Neurocrine Biosciences, Inc. (NBIX) Q4 2020 Earnings Conference Call February 04, 2021 04:30 PM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eiry Roberts - Chief Medical Officer Eric Be...
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Neurocrine Biosciences, Inc. 2020 Q4 - Results - Earnings Call Presentation
Neurocrine Biosciences (NBIX): Q4 Non-GAAP EPS of $0.91 beats by $0.01; GAAP EPS of $3.58 beats by $2.97.Revenue of $247.9M (+1.6% Y/Y) misses by $12.06M.At December 31, 2020, the Company had cash, cash equivalents and debt securities available-for-sale of $1B.Press Release For further deta...
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results Total Annual Revenues in 2020 Grew 33% to Over $1 Billion INGREZZA® (valbenazine) Full Year 2020 Net Product Sales and TRx Both Grew 32% to $993 Million and Approximately 175,700 TRx, Res...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...